Australia markets open in 2 hours 46 minutes
  • ALL ORDS

    7,306.00
    -38.20 (-0.52%)
     
  • AUD/USD

    0.7785
    +0.0037 (+0.47%)
     
  • ASX 200

    7,061.70
    -34.10 (-0.48%)
     
  • OIL

    64.86
    -0.77 (-1.17%)
     
  • GOLD

    1,815.50
    +31.20 (+1.75%)
     
  • BTC-AUD

    72,108.78
    -1,499.08 (-2.04%)
     
  • CMC Crypto 200

    1,458.59
    -12.82 (-0.87%)
     

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 18, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design and statistical problems. The pimavanserin sNDA did not contain the support for its approval despite the Company telling investors that it did. As a result, the FDA was unlikely to approve the sNDA as it was submitted. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Acadia, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422006065/en/

Contacts

The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com